{"altmetric_id":4693283,"selected_quotes":["Roche to Start PhI Combo Study of MPDL3280A (PD-L1) + erlotinib (Tarceva) in #NSCLC - #LCSM $BMY $MRK","Roche to Start PhI combo study of MPDL3280A(Anti-PD-L1) + Tarceva in #NSCLC #LCSM $BMY $MRK"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Hoffmann-La Roche"],"first_seen_on":"2015-10-28T15:15:31+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1482598156,"links":["http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02013219","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02013219?term=Alectinib&cntry1=EU%3AGB&rank=3"],"nct_id":"NCT02013219","pubdate":"2013-12-11T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Study of the Safety and Pharmacology of Combined MPDL3280A and Tarceva Treatment in Patients With Non-Small Cell Lung Cancer","type":"clinical_trial_study_record"},"altmetric_score":{"score":4.35,"score_history":{"1y":1,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":4.35},"context_for_score":{"all":{"total_number_of_other_articles":7931561,"mean":6.7081498191978,"rank":1616565,"this_scored_higher_than_pct":79,"this_scored_higher_than":6304332,"rank_type":"exact","sample_size":7931561,"percentile":79},"similar_age_3m":{"total_number_of_other_articles":241977,"mean":9.6469340099844,"rank":58545,"this_scored_higher_than_pct":75,"this_scored_higher_than":182958,"rank_type":"exact","sample_size":241977,"percentile":75},"this_journal":{"total_number_of_other_articles":21852,"mean":10.407321770171,"rank":6362,"this_scored_higher_than_pct":70,"this_scored_higher_than":15473,"rank_type":"exact","sample_size":21852,"percentile":70},"similar_age_this_journal_3m":{"total_number_of_other_articles":1052,"mean":14.52764414843,"rank":344,"this_scored_higher_than_pct":67,"this_scored_higher_than":707,"rank_type":"exact","sample_size":1052,"percentile":67}}},"demographics":{"poster_types":{"member_of_the_public":3,"researcher":1,"science_communicator":2},"users":{"twitter":{"cohorts":{"Members of the public":3,"Science communicators (journalists, bloggers, editors)":2,"Scientists":1}}},"geo":{"twitter":{"US":1}}},"counts":{"total":{"posts_count":6},"twitter":{"unique_users_count":6,"unique_users":["Docbkw","JacobEPVantage","BioMedStock","j_jay_z","lil_lytnin","AndyBiotech"],"posts_count":6}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/Docbkw\/status\/473194245243682816","license":"datasift","rt":["AndyBiotech"],"citation_ids":[4693283],"posted_on":"2014-06-01T20:07:54+00:00","author":{"name":"Brenda Watson","image":"https:\/\/pbs.twimg.com\/profile_images\/621880556490395648\/v-eLSUGH_normal.jpg","description":"Advocate for Compassionate use reform for all cancers for every age. A soldier in Andi's Army working to get drug companies 2 allow the use of drugs people need","id_on_source":"Docbkw","tweeter_id":"362356958","geo":{"lt":null,"ln":null},"followers":749},"tweet_id":"473194245243682816"},{"url":"http:\/\/twitter.com\/JacobEPVantage\/status\/413048691558072320","license":"public","rt":["AndyBiotech"],"citation_ids":[4693283],"posted_on":"2013-12-17T20:50:56+00:00","author":{"name":"Jacob Plieth","url":"http:\/\/www.epvantage.com\/default.aspx","image":"https:\/\/pbs.twimg.com\/profile_images\/453547761401462784\/a2Lp0d3m_normal.jpeg","description":"Journalist covering biopharma at EP Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.","id_on_source":"JacobEPVantage","tweeter_id":"873399943","geo":{"lt":null,"ln":null},"followers":7501},"tweet_id":"413048691558072320"},{"url":"http:\/\/twitter.com\/BioMedStock\/status\/413009351549280256","license":"datasift","citation_ids":[4693283],"posted_on":"2013-12-17T18:14:37+00:00","author":{"name":"BioMed Intelligence","url":"https:\/\/twitter.com\/BioMedStock","image":"http:\/\/pbs.twimg.com\/profile_images\/378800000773191026\/c80494c642891ba6c48fd3a136034cb3_normal.png","id_on_source":"BioMedStock","tweeter_id":"1595045330","followers":0},"tweet_id":"413009351549280256"},{"url":"http:\/\/twitter.com\/j_jay_z\/status\/413122235797606400","license":"public","rt":["AndyBiotech"],"citation_ids":[4693283],"posted_on":"2013-12-18T01:43:11+00:00","author":{"name":"joyz","image":"https:\/\/pbs.twimg.com\/profile_images\/512086208214605825\/yL1wweGf_normal.jpeg","id_on_source":"j_jay_z","tweeter_id":"229862784","geo":{"lt":null,"ln":null},"followers":90},"tweet_id":"413122235797606400"},{"url":"http:\/\/twitter.com\/lil_lytnin\/statuses\/812701688708689920","license":"gnip","citation_ids":[4693283],"posted_on":"2016-12-24T16:49:16+00:00","author":{"name":"Tori Tomalia","url":"http:\/\/lil-lytnin.blogspot.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/646341517309685760\/HpOPGIua_normal.jpg","description":"Mom, theatre artist, stage IV #LungCancer ROS1 blogger. http:\/\/Facebook.com\/LungCancerBlogger","id_on_source":"lil_lytnin","tweeter_id":"1956895806","geo":{"lt":42.27756,"ln":-83.74088,"country":"US"},"followers":1430},"tweet_id":"812701688708689920"},{"url":"http:\/\/twitter.com\/AndyBiotech\/status\/413048622884737024","license":"public","citation_ids":[4693283],"posted_on":"2013-12-17T20:50:40+00:00","author":{"name":"Andy Biotech","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000074240482\/d961ebeb9f4fe6b084a68663b9a36738_normal.png","description":"#Biotech Investor | Recovering Scientist | May have positions in mentioned names | Opinions are strictly my own and not intended as investment advice","id_on_source":"AndyBiotech","tweeter_id":"632341632","geo":{"lt":null,"ln":null},"followers":31525},"tweet_id":"413048622884737024"}]}}